RxDoctor Payments Data

Arvind Garg, MD

Nephrology · la Crosse, WINPI 1154551968

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (42.5%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 49.1% of the total. Reporting peaked in 2020 at $4,136 and has fallen 91.7% since, to $344 in 2025. Among nephrology clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,550in general payments, 2019–2025

Across 34 payments — averaging $251.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$4K
  • Outset Medical Inc$4K
  • AstraZeneca$275
  • Amgen$155
  • Nxstage Medical, Inc.$73
  • Ardelyx, Inc.$55
  • plus $162 from 7 others

What the payments were for

  • Consulting fees$3,63142%
  • Speaking & faculty fees$3,04136%
  • Travel & lodging$7739%
  • Food & beverage$1,04212%
  • Education$631%

General payments by program year

19
20
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,550 in reported general payments places this provider in the 90th percentile of 173 nephrology providers in Wisconsin.

See all nephrology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$181,422
Medicare patients
371
Services billed
1,262

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JynarqueTolvaptan11$222,640
JardianceEmpagliflozin36$27,636
KerendiaFinerenone13$9,983
InvokanaCanagliflozin12$9,159
Sevelamer Carbonate49$4,847
Calcitriol185$3,017
Torsemide133$2,125
Doxazosin Mesylate96$1,344
Bumetanide49$1,244
Losartan Potassium144$1,022
Midodrine Hcl22$980
Potassium Citrate ErPotassium Citrate25$975
Potassium Chloride65$813
Mycophenolate Mofetil12$798
Amlodipine Besylate137$669

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Jynarque$4,199$222,64011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 173 nephrology providers in Wisconsin.

Other nephrology in la Crosse

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →